· daily
US SEC Trading Suspension Halt Orders — August 28, 2026
This digest covers 12 filings related to US trading suspensions, delistings, and regulatory halts, all concentrated on August 24-28, 2026. A dominant theme is the wave of Nasdaq non-compliance notices, with 10 of 12 filings involving Nasdaq-listed companies facing issues ranging from late filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) to bid price deficiencies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) and equity shortfalls (My Size, Socket Mobile). Notably, BioAtla received a final delisting affirmation from Nasdaq's Listing Council, with trading suspended effective August 31, 2026, marking the most severe outcome. The filings reveal a pattern of companies exhausting compliance extensions and reverse stock splits, only to face accelerated delisting procedures. Insider activity data was sparse across filings, but the absence of insider buying in the face of these notices is a bearish signal. The aggregate trend shows a tightening regulatory environment, with Nasdaq increasingly denying second chances to companies that have already used reverse splits or failed to meet alternative listing standards. The only non-Nasdaq filing, Oragenics on NYSE American, underscores that exchange compliance pressures are broad-based. Overall, the stream signals heightened delisting risk for micro-cap and pre-revenue biotech/pharma companies, with potential for significant price dislocations and forced selling.
12 high priority
12 total filings